ID–MAM: A Validated Identity and Multi-Attribute Monitoring Method for Commercial Release and Stability Testing of a Bispecific Antibody

• Published in: Analytical chemistry (Washington) Vol. 93; no. 26; pp. 9166 - 9173
• Main Authors: Evans, Adam R, Hebert, Alexander S, Mulholland, Joseph, Lewis, Michael J, Hu, Ping
• Format: Journal Article
• Language: English
• Published: Washington American Chemical Society 06.07.2021
• Subjects: Antibodies; Bispecific antibodies; Chemistry; Data processing; High resolution; Isomerization; Mass spectrometers; Mass spectrometry; Mass spectroscopy; Monitoring; Oxidation; Peptide mapping; Peptides; Post-translation; Product development; Quality control; Quality management; Quantitation; Spectrometers; Stability; Workflow
• ISSN: 0003-2700; 1520-6882
• DOI: 10.1021/acs.analchem.1c01029

Post-translational modifications (PTMs) that impact the safety or efficacy of protein therapeutics are critical quality attributes (CQAs) that need to be controlled to ensure product quality. Peptide mapping with online mass spectrometry (MS) is a powerful tool that has been used for many years to monitor PTM CQAs during product development. However, operating peptide mapping methods with high-resolution mass spectrometers in GMP compliant, commercial quality control (QC) labs can be difficult. Peptide mapping is also required as an identity test in several countries. To address these two different needs, we utilized high-resolution peptide mapping for comprehensive characterization during development and then developed and validated a targeted multi-attribute monitoring (MAM) method using the low-resolution Waters QDa MS system with a fully automated data processing workflow that is suitable for identity (ID) testing, sequence variant control, and CQA quantitation in commercial QC labs. The ID–MAM method was validated for the quantitation of three selected PTM CQAs (CDR isomerization, Fc Met oxidation, and CDR Met oxidation) to ensure control of the oxidation and isomerization degradation pathways of a bispecific antibody (BsAb). This ID–MAM method was successfully validated in six labs (three analytical development and three QC labs) across four countries for commercial release and stability testing of a BsAb. CQA results obtained with the ID–MAM method were similar to results obtained using high-resolution peptide mapping, and the method was robust and reproducible. To our knowledge, this ID–MAM method is the first MS-based peptide mapping method implemented in GMP compliant QC labs for commercial release and stability testing of a biotherapeutic.